The nation of Zimbabwe has turned down a substantial American health deal valued at $367m (272 million pounds) over five years because of Washington's demand for confidential data.
The decision was revealed after a official document from December was disclosed, which showed President Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesperson has since stated that the US was seeking genetic material for research and commercial gain while refused to share the benefits from future medical innovations.
"We are forced to start the challenging and unfortunate task of scaling back our support in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the United States had furnished over $1.9bn in health funding to Zimbabwe over the last twenty years.
A doctors' association in Zimbabwe has called for further dialogue to find a deal acceptable to both sides so the country's vital HIV programme can continue.
Wider Background
Zimbabwe's decision follows a similar situation in Kenya, where a high court halted a related health funding agreement following concerns were raised about the security of citizens' health data.
Since returning to the presidency recently, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump stated its spending was "wasteful" and his administration was pursuing direct bilateral agreements to boost openness and accountability.
According to statements, 16 African countries have to date agreed to similar agreements, constituting over $18.3bn in committed funds.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to supported "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided significant advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy via US-supported initiatives," the Ambassador said.
However, official spokesman Nick Mangwana maintained the proposed deal was "unequal".
"Zimbabwe was being asked to share its biological resources and data for a long time, without any equivalent assurance of access to any medical innovations – such as vaccines, diagnostics, or treatments – that might be developed from that shared data," Mangwana explained.
"Put simply, our country would supply the raw materials for medical research without any certainty that the final treatments would be available to our people if a new pandemic arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its pursuit of bilateral deals were disrupting frameworks already set up via the international organization.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme created to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation contributes its samples, the resulting advantages – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to develop them."
Zimbabwe's reservations regarding the US deal "are not meant as anti-American sentiment," he added.
"We encourage further dialogue with our American counterparts on how future co-operation could be arranged in a manner that respects the sovereignty and dignity of both nations."
Health Experts Response
A leading public health body stated it recognised the official position, but suggested that negotiations need to persist given that a large portion of the country's HIV programmes depended on international support.
"Where specific concerns exist, including those involving data governance or agreement terms, these can often be addressed through detailed discussion and mutually agreed protections," it commented.
The halted deal highlights the continuing tensions between accepting vital foreign assistance and safeguarding a country's data in an ever more data-driven world.